Tirzepatide (GLP-2) vs Semaglutide: Mechanism, Specs & Reported Ranges Compared
Side-by-side comparison of Tirzepatide (GLP-2) and Semaglutide — receptor mechanism, half-life, vial sizes, reconstitution and reported study arms.
By PX1 Research Team · August 4, 2026
Tirzepatide (GLP-2) vs Semaglutide at a glance
| Tirzepatide (GLP-2) | Semaglutide | |
|---|---|---|
| Class | dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Reported half-life | ~5 days | ~7 days |
| Vial sizes | 10 mg / 15 mg / 30 mg / 60 mg | 5 mg / 10 mg |
| Typical reconstitution | 10 mg + 2 mL = 5 mg/mL | 5 mg + 2 mL = 2.5 mg/mL |
| Research focus | incretin and metabolic research | GLP-1 receptor research |
Mechanistic difference
Tirzepatide adds GIP receptor activity to the GLP-1 mechanism semaglutide uses alone. Published protocols escalate tirzepatide in 2.5 mg steps versus semaglutide's sub-milligram steps.
Reported study ranges side by side
Tirzepatide (GLP-2)
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 2.5 mg | weekly × 4 |
| Step 1 | 5 mg | weekly × 4 |
| Step 2 | 7.5 mg | weekly × 4 |
| Step 3 | 10 mg | weekly × 4 |
| Maximal arms | 15 mg | weekly |
Semaglutide
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 0.25 mg | weekly × 4 |
| Step 1 | 0.5 mg | weekly × 4 |
| Step 2 | 1 mg | weekly × 4 |
| Step 3 | 1.7 mg | weekly × 4 |
| Maximal arms | 2.4 mg | weekly |
Practical handling differences
Both arrive lyophilized and shelf-stable. Tirzepatide (GLP-2) is typically prepared at 10 mg + 2 mL = 5 mg/mL; Semaglutide at 5 mg + 2 mL = 2.5 mg/mL. Where half-lives differ, the literature's dosing cadence differs accordingly — longer-acting molecules are described weekly, shorter-acting ones daily or split.
Which one appears in which research context
Tirzepatide (GLP-2) shows up primarily in incretin and metabolic research. Semaglutide is used in GLP-1 receptor research. They are not interchangeable substitutes; the receptor profile, not the marketing category, determines where each is used.
Documentation and sourcing
Both are supplied at ≥99% HPLC purity with lot-level COAs at /coa. Product pages: Tirzepatide (GLP-2) · Semaglutide.
How PX1 documents every lot
Every PX1 lot ships with HPLC purity, LC-MS identity, residual solvent, moisture (Karl Fischer), sterility and endotoxin data. Lot documentation is published at /purity-reports, /endotoxin-reports and /coa. Synthesis, purification, lyophilization and vial fill happen in U.S. facilities — see /manufacturing-process.
Research use only. PX1 Research supplies compounds for laboratory and in-vitro research. Nothing here is medical advice, a dosing recommendation, or an offer for human or veterinary use. Figures cited are reported from published laboratory literature.